Nautilus Biotechnology, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period
Nautilus Biotechnology, Inc. (NAUT) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period of 923.29 thousand shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-28.
Financial Statements › Shareholders' Equity › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod · last filed 2026-07-28
- Nautilus Biotechnology, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2026-06-30 was 766.46K shares, a 9.32% increase year-over-year.
- Nautilus Biotechnology, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2026-03-31 was 156.83K shares, a 57.65% decline year-over-year.
- Nautilus Biotechnology, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2025-12-31 was 65.61K shares, a 85.50% decline year-over-year.
- Nautilus Biotechnology, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2025-09-30 was 1.77M shares, a 212.50% increase year-over-year.
- Nautilus Biotechnology, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2025 was 2.91M shares, a 113.99% increase from fiscal 2024.
- Nautilus Biotechnology, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2024 was 1.36M shares, a 81.86% increase from fiscal 2023.
- Nautilus Biotechnology, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2023 was 748.02K shares, a 41.51% decline from fiscal 2022.
- Nautilus Biotechnology, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2022 was 1.28M shares, a 109.26% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 12 month |
|---|---|---|---|---|
| 2026-06-30 | 766.46K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-28 | 923.29K shares 10-Q · filed 2026-07-28 | 988.90K shares derived: sum of 3 quarters · filed 2026-07-28 | 2.76M shares derived: sum of 4 quarters · filed 2026-07-28 |
| 2026-03-31 | 156.83K shares 10-Q · filed 2026-04-28 | 222.44K shares derived: sum of 2 quarters · filed 2026-04-28 | 2.00M shares derived: sum of 3 quarters · filed 2026-04-28 | 2.70M shares derived: sum of 4 quarters · filed 2026-04-28 |
| 2025-12-31 | 65.61K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | 1.84M shares derived: sum of 2 quarters · filed 2026-02-26 | 2.54M shares derived: sum of 3 quarters · filed 2026-02-26 | 2.91M shares 10-K · filed 2026-02-26 |
| 2025-09-30 | 1.77M shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-28 | 2.48M shares derived: sum of 2 quarters · filed 2025-10-28 | 2.85M shares 10-Q · filed 2025-10-28 | 3.30M shares derived: sum of 4 quarters · filed 2025-10-28 |
| 2025-06-30 | 701.13K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-07-31 | 1.07M shares 10-Q · filed 2025-07-31 | 1.52M shares derived: sum of 3 quarters · filed 2025-07-31 | 2.09M shares derived: sum of 4 quarters · filed 2025-07-31 |
| 2025-03-31 | 370.31K shares 10-Q · filed 2025-04-29 | 822.84K shares derived: sum of 2 quarters · filed 2025-04-29 | 1.39M shares derived: sum of 3 quarters · filed 2025-04-29 | 1.55M shares derived: sum of 4 quarters · filed 2025-04-29 |
| 2024-12-31 | 452.53K shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | 1.02M shares derived: sum of 2 quarters · filed 2025-02-27 | 1.18M shares derived: sum of 3 quarters · filed 2025-02-27 | 1.36M shares 10-K · filed 2025-02-27 |
| 2024-09-30 | 567.67K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-29 | 729.07K shares derived: sum of 2 quarters · filed 2024-10-29 | 907.82K shares 10-Q · filed 2024-10-29 | 1.19M shares derived: sum of 4 quarters · filed 2024-10-29 |
| 2024-06-30 | 161.40K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-07-30 | 340.15K shares 10-Q · filed 2024-07-30 | 627.33K shares derived: sum of 3 quarters · filed 2024-07-30 | 793.81K shares derived: sum of 4 quarters · filed 2024-07-30 |
| 2024-03-31 | 178.75K shares 10-Q · filed 2024-04-30 | 465.93K shares derived: sum of 2 quarters · filed 2024-04-30 | 632.41K shares derived: sum of 3 quarters · filed 2024-04-30 | 763.42K shares derived: sum of 4 quarters · filed 2024-04-30 |
| 2023-12-31 | 287.18K shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | 453.66K shares derived: sum of 2 quarters · filed 2024-02-28 | 584.67K shares derived: sum of 3 quarters · filed 2024-02-28 | 748.02K shares 10-K · filed 2024-02-28 |
| 2023-09-30 | 166.49K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-10-31 | 297.49K shares derived: sum of 2 quarters · filed 2023-10-31 | 460.84K shares 10-Q · filed 2023-10-31 | 628.40K shares derived: sum of 4 quarters · filed 2023-10-31 |
| 2023-06-30 | 131.00K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-02 | 294.36K shares 10-Q · filed 2023-08-02 | 461.92K shares derived: sum of 3 quarters · filed 2023-08-02 | 847.31K shares derived: sum of 4 quarters · filed 2023-08-02 |
| 2023-03-31 | 163.35K shares 10-Q · filed 2023-05-02 | 330.91K shares derived: sum of 2 quarters · filed 2023-05-02 | 716.30K shares derived: sum of 3 quarters · filed 2023-05-02 | 1.07M shares derived: sum of 4 quarters · filed 2023-05-02 |
| 2022-12-31 | 167.56K shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-23 | 552.95K shares derived: sum of 2 quarters · filed 2023-02-23 | 904.53K shares derived: sum of 3 quarters · filed 2023-02-23 | 1.28M shares 10-K · filed 2023-02-23 |
| 2022-09-30 | 385.39K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-01 | 736.97K shares derived: sum of 2 quarters · filed 2022-11-01 | 1.11M shares 10-Q · filed 2022-11-01 | 1.25M shares derived: sum of 4 quarters · filed 2022-11-01 |
| 2022-06-30 | 351.58K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-02 | 725.84K shares 10-Q · filed 2022-08-02 | 867.74K shares derived: sum of 3 quarters · filed 2022-08-02 | 1.21M shares derived: sum of 4 quarters · filed 2022-08-02 |
| 2022-03-31 | 374.26K shares 10-Q · filed 2022-05-03 | 516.16K shares derived: sum of 2 quarters · filed 2022-05-03 | 856.10K shares derived: sum of 3 quarters · filed 2022-05-03 | |
| 2021-12-31 | 141.90K shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | 481.84K shares derived: sum of 2 quarters · filed 2022-02-24 | 611.09K shares 10-K · filed 2022-02-24 | |
| 2021-09-30 | 339.94K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-02 | 469.19K shares 10-Q · filed 2021-11-02 | ||
| 2021-06-30 | 129.25K shares 10-Q · filed 2021-08-10 | |||
| 2020-12-31 | 72.53K shares 10-K · filed 2022-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Quanterix Corp (QTRX) | United States | $0.150B | -1.65 |
| Seer, Inc. (SEER) | United States | $0.104B | -1.34 |
| Precipio, Inc. (PRPO) | United States | $0.043B | -36.70 |
| HARVARD BIOSCIENCE INC (HBIO) | United States | $0.037B | -2.70 |
| Bionano Genomics, Inc. (BNGO) | United States | $0.020B | -0.42 |
| ASTROTECH Corp (ASTC) | United States | $0.013B | |
| EyePoint, Inc. (EYPT) | United States | $0.314B | -3.96 |
| 908 Devices Inc. (MASS) | United States | $0.476B | -9.53 |
| PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (PACB) | United States | $0.491B | -3.95 |
| Cytek Biosciences, Inc. (CTKB) | United States | $0.744B | -7.15 |